INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study

Key Takeaways Insmed shares rose ~6% after Arikayce met primary and secondary goals in a phase IIIb MAC lung study.INSM plans regulatory filings in the United States and Japan to expand use to newly diagnosed patients.Arikayce's market could grow from ~30K to 200K patients, supporting potential blockbuster sales.Shares of Insmed (INSM) gained nearly 6% on Monday after the company reported positive top-line results from the phase IIIb ENCORE study evaluating Arikayce for label expansion in mycobacterium aviu ...